Making sense of therapeutics using antisense technology

Expert Opinion on Drug Discovery

Volumn 6, Issue 5, 2011, Pages 507-526

  Malik, Ravinder ^a   Roy, Ipsita ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

antisense oligonucleotides; chemical modification; gene knockdown; transcriptional regulation

Indexed keywords

ACHN 490; AEG 35156; ANTISENSE OLIGONUCLEOTIDE; ATL 1102; ATL 1103; AVI 4020; AVI 4126; AVI 4412; AVI 4413; AVI 4557; AVI 4658; AVI 6002; AVI 6003; BMS PCSK 9; CUSTIRSEN; DENDRIMER; EXC 001; ICO 007; ISIS 113715; ISIS CRP; ISIS FXI; ISIS GCCR; ISIS SMN; LY 2181308; MESSENGER RNA; MG 98; MIPOMERSEN; NANOPARTICLE; OGX 427; TRABEDERSEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIFUNGAL ACTIVITY; ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; CHEMICAL MODIFICATION; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HYPERCHOLESTEROLEMIA; METABOLIC DISORDER; NEOPLASM; NEUROMUSCULAR DISEASE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; WOUND HEALING;

EID: 79955453676     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2011.565744     Document Type: Review

References (118)

1. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8 (Pubitemid 32494397)
2. Kruger K, Grabowski PJ, Zaug AJ, et al. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982;31:147-57 (Pubitemid 13215202)
3. Lundblad EW, Altman S. Inhibition of gene expression by RNase P. Nat Biotechnol 2010;27:212-21
4. Lavorgna G, Dahary D, Lehner B, et al. In search of antisense. Trends Biochem Sci 2004;29:88-94 (Pubitemid 38186579)
5. Lindberg J, Lundeberg J. The plasticity of the mammalian transcriptome. Genomics 2010;95:1-6
6. Werner A, Swan D. What are natural antisense transcripts good for? Biochem Soc Trans 2010;38:1144-9
7. Su WY, Xiong H, Fang JY. Natural antisense transcripts regulate gene expression in an epigenetic manner. Biochem Biophys Res Commun 2010;396:177-81
8. Rossignol F, Vache C, Clottes E. Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues. Gene 2002;299:135-40 (Pubitemid 35379835)
9. Kimura T, Shiwen J, Nishizawa M, et al. A natural antisense transcript of interferon-alpha1 gene regulates viral infection-mediated mRNA expression level and further induction of interferon-alpha1 protein. Cytokine 2009;48:124
10. Smalheiser NR, Lugli G, Torvik VI, et al. Natural antisense transcripts are co-expressed with sense mRNAs in synaptoneurosomes of adult mouse forebrain. Neurosci Res 2008;62:236-9
11. Kurihara N, Hiruma Y, Yamana K, et al. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Pagets disease. Cell Metab 2011;13:23-34
12. Hadad N, Tuval L, Elgazar-Carmom V, et al. Endothelial ICAM-1 protein induction is regulated by cytosolic phospholipase A2alpha via both NF-kappaB and CREB transcription factors. J Immunol 2011;186:1816-27
13. Malik R, Roy I. Design and development of antisense drugs. Expert Opin Drug Discov 2008;3:1189-207
14. Bunka DH, Platonova O, Stockley PG. Development of aptamer therapeutics. Curr Opin Pharmacol 2010;10:557-62
15. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 1988;85:5011-15
16. Borchelt D, Perdue ML. Influence of base-pairing in the leader region on in vitro translation of Rous sarcoma virus RNA. Virus Res 1985;3:141-51 (Pubitemid 15233694)
17. Alotte C, Martin A, Caldarelli SA, et al. Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro. Antiviral Res 2008;80:280-7
18. Kumar M, Carmichael GG. Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts. Proc Natl Acad Sci USA 1997;94:3542-7 (Pubitemid 27180408)
19. Werner A, Berdal A. Natural antisense transcripts: sound or silence? Physiol Genomics 2005;23:125-31 (Pubitemid 44437972)
20. Mattes J, Yang M, Foster PS. Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function? Am J Respir Cell Mol Biol 2007;36:8-12 (Pubitemid 46067702)
21. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with antagomirs. Nature 2005;438:685-9
22. Flores-Aguilar M, Besen G, Vuong C, et al. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J Infect Dis 1997;175:1308-16 (Pubitemid 27225032)
23. Steininger C. Novel therapies for cytomegalovirus disease. Recent Pat Antiinfect Drug Discov 2007;2:53-72 (Pubitemid 46729087)
24. Menke J, Bork T, Kutska B, et al. Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int 2011;79:452-63
25. Ansari MA, Dhar M, Muthukrishnan V, et al. Administration of antisense oligonucleotides to Galpha(Q/11) reduces the severity of murine lupus. Biochimie 2003;85:627-32 (Pubitemid 36798237)
26. Jacobson JD. Gonadotropin-releasing hormone: potential role in autoimmunity. Int Immunopharmacol 2001;1:1077-83 (Pubitemid 32434425)
27. Diaz-Gallo L, Gourh P, Broen J, et al. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 2011;70:454-62
28. Delogu LG, Magrini A, Bergamaschi A, et al. Conjugation of antisense oligonucleotides to PEGylated carbon nanotubes enables efficient knockdown of PTPN22 in T lymphocytes. Bioconjug Chem 2009;20:427-31
29. Sussman JD, Argov Z, McKee D, et al. Antisense treatment for myasthenia gravis: experience with monarsen. Ann NY Acad Sci 2008;1132:283-90 (Pubitemid 351841365)
30. Hong HJ, Jin SE, Park JS, et al. Accelerated wound healing by smad3 antisense oligonucleotides-impregnated chitosan/ alginate polyelectrolyte complex. Biomaterials 2008;29:4831-7
31. Ugarte M, Aguado C, Desviat LR, et al. Propionic and methylmalonic acidemia: Antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. Am J Hum Genet 2007;81:1262-70 (Pubitemid 350211454)
32. Perez B, Rodriguez-Pascau L, Vilageliu L, et al. Present and future of antisense therapy for splicing modulation in inherited metabolic disease. J Inherit Metab Dis 2010;33:397-403
33. Zhou SH, Fan J, Chen XM, et al. Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 2009;31:1624-33
34. Zhao FJ, Zhang SL, Ma L, et al. Inhibitory effects of c-erbB-2 antisense oligonucleotide transfection on uterine endometrial cancer Ishikawa cell lines. Eur J Gynaecol Oncol 2009;30:54-9
35. Available from: www.avibio.com.
36. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97:1287-96 (Pubitemid 41535369)
37. Chi KN, Siu LL, Hirte H, et al. A phase I study of OGX-011, a 2-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14:833-9 (Pubitemid 351231167)
38. Olivares J, Kumar P, Yu Y, et al. Phase I trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 2011;17:183-92
39. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802
40. Wang W, Sima N, Kong D, et al. Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo. Cancer Lett 2010;291:67-75
41. Lee S, Kim JH, Kim H, et al. Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expressionof interleukin-32 controls the expression of the humanpapillomavirus oncogene. Immunology 2011;132:410-20
42. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010;16:991-4
43. Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 2002;196:1381-6 (Pubitemid 35375557)
44. Ripple MJ, You D, Honnegowda S, et al. Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease. J Immunol 2010;185:4804-11
45. Qureshi A, Zheng R, Parlett T, et al. Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA. Biochem J 2006;394:511-18 (Pubitemid 43342552)
46. Bell DA, Hooper AJ, Burnett JR. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs 2011;20:265-72
47. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105:1413-19
48. Trial watch. Antisense agent reduces LDL-cholesterol levels in high-risk patients. Nat Rev Drug Discov 2010;9:10
49. Duff CJ, Hooper NM. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets 2011;15:157-68
50. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007;48:763-7 (Pubitemid 46557881)
51. Gupta N, Fisker N, Asselin MC, et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010;5:e10682
52. Aartsma-Rus A, van Ommen GJ. Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet 2010;18:146-53
53. Rimessi P, Fabris M, Bovolenta M, et al. Antisense modulation of both exonic and intronic splicing motifs induces skipping of a DMD pseudo-exon responsible for X-linked dilated cardiomyopathy. Hum Gene Ther 2010;21:1137-46
54. Wheeler TM, Lueck JD, Swanson MS, et al. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007;117:3952-7 (Pubitemid 350224104)
55. Kelley NW, Huang X, Tam S, et al. The predicted structure of the headpiece of the Huntingtin protein and its implications on Huntingtin aggregation. J Mol Biol 2009;388:919-27
56. Cattaneo E, Rigamonti D, Goffredo D, et al. Loss of normal huntingtin function: new developments in Huntingtons disease research. Trends Neurosci 2001;24:182-8 (Pubitemid 32166824)
57. Gagnon KT, Pendergraff HM, Deleavey GF, et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 2010;49:10166-78
58. Zhang L, Leibowitz MJ, Zhang Y. Antisense oligonucleotides effectively inhibit the co-transcriptional splicing of a Candida group I intron in vitro and in vivo: implications for antifungal therapeutics. FEBS Lett 2009;583:734-8
59. Xu L, Anchordoquy T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci 2011;100:38-52
60. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-38
61. Zhao X, Pan F, Holt CM, et al. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert Opin Drug Deliv 2009;6:673-86
62. Li Q, Yuan F, Zhou C, et al. Free-radical ring closure to conformationally locked alpha-L-carba- LNAs and synthesis of their oligos: nuclease stability, target RNA specificity, and elicitation of RNase H. J Org Chem 2010;75:6122-40
63. Winkler J, Gilbert M, Kocourkova A, et al. 2-O-Lysylaminohexyl oligonucleotides: modifications for antisense and siRNA. ChemMedChem 2008;3:102-10
64. Zhang X, Koh CG, Yu B, et al. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide G3139 in a murine k562 xenograft model. Pharm Res 2009;26:1516-24
65. Mehiri M, Upert G, Tripathi S, et al. An efficient biodelivery system for antisense polyamide nucleic acid (PNA). Oligonucleotides 2008;18:245-56
66. Hatamoto M, Ohashi A, Imachi H. Peptide nucleic acids (PNAs) antisense effect to bacterial growth and their application potentiality in biotechnology. Appl Microbiol Biotechnol 2010;86:397-402
67. Khatsenko O, Morgan R, Truong L, et al. Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length. Antisense Nucleic Acid Drug Dev 2000;10:35-44 (Pubitemid 30148188)
68. Raoof AA, Ramtoola Z, McKenna B, et al. Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci 2002;17:131-8 (Pubitemid 35248266)
69. Raoof AA, Chiu P, Ramtoola Z, et al. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci 2004;93:1431-9 (Pubitemid 38725017)
70. Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J Pharm Sci 2008;97:225-36
71. Bantel-Schaal U. Integration of adeno-associated virus 2 DNA in human MKR melanoma cells induces a peptide with oncosuppressive properties. Int J Cancer 2001;92:537-44 (Pubitemid 32319427)
72. Denti MA, Incitti T, Sthandier O, et al. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther 2008;19:601-8 (Pubitemid 351913531)
73. Sun X, Jiang H, Jiang X, et al. Antisense hypoxia-inducible factor-1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats. Hum Gene Ther 2009;20:314-24
74. Williams KJ, Telfer BA, Xenaki D, et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 2005;75:89-98 (Pubitemid 40616800)
75. Brown CY, Sadlon T, Gargett T, et al. Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector. Hum Gene Ther 2010;21:1005-17
76. Ravina M, Paolicelli P, Seijo B, et al. Knocking down gene expression with dendritic vectors. Mini Rev Med Chem 2010;10:73-86
77. Wang P, Zhao XH, Wang ZY, et al. Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment. Cancer Lett 2010;298:34-49
78. Ljubimova JY, Lakhter AJ, Loksh A, et al. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res 2001;61:5601-10 (Pubitemid 32694948)
79. Ding H, Inoue S, Ljubimov AV, et al. Inhibition of brain tumor growth by intravenous poly(beta-L-malic acid) nanobioconjugate with pH-dependent drug release. Proc Natl Acad Sci USA 2010;107:18143-8
80. Garbuzenko OB, Saad M, Pozharov VP, et al. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 2010;107:10737-42
81. Ozbas-Turan S, Akbuga J, Sezer AD. Topical application of antisense oligonucleotide-loaded chitosan nanoparticles to rats. Oligonucleotides 2010;20:147-53
82. Elhamess H, Bertrand JR, Maccario J, et al. Antitumor vectorized oligonucleotides in a model of ewing sarcoma: unexpected role of nanoparticles. Oligonucleotides 2009;19:255-64
83. Hagigit T, Abdulrazik M, Orucov F, et al. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J Control Release 2010;145:297-305
84. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-32
85. Klang S, Abdulrazik M, Benita S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol 2000;5:521-32
86. Berthold PR, Shiraishi T, Nielsen PE. Cellular delivery and antisense effects of peptide nucleic acid conjugated to polyethyleneimine via disulphide linkers. Bioconjug Chem 2010;21:1933-8
87. Kang H, Alam MR, Dixit V, et al. Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier. Bioconjug Chem 2008;19:2182-8
88. Zou J, Qiao X, Ye H, et al. Inhibition of ataxia-telangiectasia mutated by antisense oligonucleotide nanoparticles induces radiosensitization of head and neck squamous-cell carcinoma in mice. Cancer Biother Radiopharm 2009;24:339-46
89. Thomas SM, Ogagan MJ, Freilino ML, et al. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Mol Pharmacol 2008;73:627-38 (Pubitemid 351397868)
90. Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:4247-54
91. Bilanges B, Stokoe D. Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem J 2005;388:573-83 (Pubitemid 40839935)
92. Xie SY, Ren ZR, Zhang JZ, et al. Restoration of the balanced alpha/betaglobin gene expression in beta654-thalassemia mice using combined RNAi and antisense RNA approach. Hum Mol Genet 2007;16:2616-25
93. Higgs DR, Thein SL, Woods WG. The molecular pathology of the thalassemias. In: Weatherall DJ, Clegg B, editors, The thalassemia syndromes. 4th edition. Blackwell Science, Oxford; 2001. p. 133-91
94. Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet 2004;5:355-65 (Pubitemid 38529407)
95. Williams BR. Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Biochem Soc Trans 1997;25:509-13 (Pubitemid 27260861)
96. Player MR, Torrence PF. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther 1998;78:55-113 (Pubitemid 28202386)
97. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003;4:457-67 (Pubitemid 36648591)
98. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200 (Pubitemid 32107664)
99. Chi JT, Chang HY, Wang NN, et al. Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci USA 2003;100:6343-6 (Pubitemid 36666583)
100. Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9 (Pubitemid 37087172)
101. Availaible from: www.isip.com
102. Availaible from: www.genzyme.com
103. Tamm I. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer. Curr Opin Investig Drugs 2008;9:638-46 (Pubitemid 351777167)
104. Availaible from: www.antisensepharma. de
105. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-{beta}2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neurooncol 2010;13:132-42
106. Available from: www.tevapharm.com
107. Available from: www.oncogenex.ca.
108. Available from: www.bms.com.
109. Available from: www.excaliard.com.
110. Available from: www.lilly.com
111. Available from: www.enzo.com.
112. Plummer R, Vidal L, Griffin M, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 2009;15:3177-83
113. Dong L, Xia S, Chen H, et al. Spleen-specific suppression of TNF-alpha by cationic hydrogel-delivered antisense nucleotides for the prevention of arthritis in animal models. Biomaterials 2009;30:4416-26
114. Wang J, Tao X, Zhang Y, et al. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. Biomaterials 2010;31:4426-33
115. Wei B, Wei Y, Zhang K, et al. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. Biomed Pharmacother 2009;63:313-18
116. Koppelhus U, Shiraishi T, Zachar V, et al. Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain. Bioconjug Chem 2008;19:1526-34
117. Pillai VC, Yesudas R, Shaik IH, et al. Delivery of NADPH-cytochrome P450 reductase antisense oligos using avidin-biotin approach. Bioconjug Chem 2010;21:203-7
118. Yin H, Moulton HM, Betts C, et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009;18:4405-14